Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

K. Belhadj · SciRah

Researcher profile · Semantic Scholar

K. Belhadj

Share profile

K. Belhadj — researcher profile on SciRah

h-index: 45
Works: 164
Citations: 9,936

Most-cited papers

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation in Myeloma.
M. Attal, V. Lauwers-Cancès, C. Hulin, X. Leleu +22 more
2017New England Journal of Medicine1,109 citations Open access
Semantic Scholar
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
P. Moreau, M. Attal, C. Hulin, B. Arnulf +54 more
2019The Lancet828 citations Open access
Semantic Scholar
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
A. Perrot, V. Lauwers-Cancès, J. Corre, N. Robillard +36 more
2018Blood383 citations Open access
Semantic Scholar
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
P. Moreau, C. Hulin, M. Macro, D. Caillot +38 more
2016Blood267 citations Open access
Semantic Scholar
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
C. Copie-Bergman, P. Cuillière-Dartigues, M. Baia, J. Briére +19 more
2015Blood243 citations
Semantic Scholar
Follicular Peripheral T-cell Lymphoma Expands the Spectrum of Classical Hodgkin Lymphoma Mimics
J. Moroch, C. Copie-Bergman, L. D. de Leval, A. Plonquet +9 more
2012American Journal of Surgical Pathology183 citations
Semantic Scholar
The Genetic Basis of Hepatosplenic T Cell Lymphoma
Matthew Mckinney, Andrea B. Moffitt, P. Gaulard, M. Travert +52 more
2017Cancer Discovery181 citations Open access
Semantic Scholar
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.
A. Perrot, V. Lauwers-Cancès, E. Tournay, C. Hulin +25 more
2019Journal of Clinical Oncology144 citations Open access
Semantic Scholar
Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)
M. Attal, V. Lauwers-Cancès, C. Hulin, T. Facon +14 more
2015121 citations
Semantic Scholar
Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use.
J. Kwun, M. Matignon, M. Manook, S. Guendouz +20 more
2019Journal of the American Society of Nephrology115 citations Open access
Semantic Scholar
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
M. Chrétien, J. Corre, V. Lauwers-Cancès, F. Magrangeas +27 more
2015Blood115 citations Open access
Semantic Scholar
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.
B. Royer, S. Minvielle, M. Diouf, M. Roussel +24 more
2016Journal of Clinical Oncology112 citations
Semantic Scholar
Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial
A. Perrot, V. Lauwers-Cancès, T. Cazaubiel, T. Facon +18 more
2020108 citations Open access
Semantic Scholar
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
P. Moreau, C. Hulin, A. Perrot, B. Arnulf +48 more
2021The Lancet Oncology105 citations Open access
Semantic Scholar
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.
B. Hébraud, F. Magrangeas, A. Cleynen, V. Lauwers-Cancès +21 more
2015Blood98 citations Open access
Semantic Scholar
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma
E. Bachy, R. Houot, F. Morschhauser, A. Sonet +14 more
2013Haematologica84 citations Open access
Semantic Scholar
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk
J. Corre, L. Montes, E. Martin, A. Perrot +24 more
2019Haematologica81 citations Open access
Semantic Scholar
Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.
T. Dejoie, J. Corre, H. Caillon, C. Hulin +39 more
2016Blood71 citations Open access
Semantic Scholar
Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial
H. Avet-Loiseau, J. Corre, V. Lauwers-Cancès, M. Chrétien +24 more
201566 citations
Semantic Scholar
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
L. Garderet, F. Kuhnowski, Benoît Berge, M. Roussel +33 more
2018Blood60 citations Open access
Semantic Scholar
Whole-Body Diffusion-weighted Imaging in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma.
S. Toledano-Massiah, A. Luciani, E. Itti, P. Zerbib +6 more
2015Radiographics57 citations
Semantic Scholar
Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study
P. Moreau, S. Zweegman, A. Perrot, C. Hulin +17 more
2019Blood56 citations Open access
Semantic Scholar
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
A. Schavgoulidze, A. Talbot, A. Perrot, T. Cazaubiel +23 more
2022Blood54 citations Open access
Semantic Scholar
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study
C. Hulin, F. Offner, P. Moreau, M. Roussel +19 more
2021Haematologica54 citations Open access
Semantic Scholar
Intravoxel Incoherent Motion Diffusion-weighted Imaging of Multiple Myeloma Lesions: Correlation with Whole-Body Dynamic Contrast Agent-enhanced MR Imaging.
C. Bourillon, A. Rahmouni, Chieh Lin, K. Belhadj +10 more
2015Radiology52 citations
Semantic Scholar
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma
M. Dimopoulos, M. Cheung, M. Roussel, Ting Liu +21 more
2016Haematologica47 citations Open access
Semantic Scholar
Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation
C. Cazelles, K. Belhadj, H. Vellemans, V. Camus +15 more
2021Leukemia and Lymphoma43 citations Open access
Semantic Scholar
Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma.
R. Álvarez, J. Dupuis, A. Plonquet, C. Christov +9 more
2012Annals of Oncology43 citations Open access
Semantic Scholar
Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Kr
M. Roussel, V. Lauwers-Cancès, N. Robillard, K. Belhadj +11 more
201642 citations Open access
Semantic Scholar
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy.
F. Bridoux, B. Arnulf, Lionel Karlin, N. Blin +23 more
2020Journal of Clinical Oncology39 citations
Semantic Scholar
Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study
M. Lévy, C. Copie-Bergman, A. Amiot, J. Dupuis +8 more
2013Leukemia and Lymphoma34 citations
Semantic Scholar
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
M. Roussel, B. Hébraud, C. Hulin, A. Perrot +15 more
2020Leukemia and Lymphoma28 citations Open access
Semantic Scholar
Primary Plasma Cell Leukemia displaying t(11;14) have specific genomic, transcriptional and clinical feature.
T. Cazaubiel, X. Leleu, A. Perrot, S. Manier +23 more
2022Blood27 citations Open access
Semantic Scholar
Rituximab, alkylating agents or combination therapy for gastric mucosa‐associated lymphoid tissue lymphoma: a monocentric non‐randomised observational study
A. Amiot, Michaël Lévy, C. Copie-Bergman, J. Dupuis +8 more
2014Alimentary Pharmacology and Therapeutics26 citations Open access
Semantic Scholar
Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)
M. Roussel, B. Hébraud, V. Lauwers-Cancès, M. Macro +28 more
201725 citations
Semantic Scholar
Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study
F. Kraeber-Bodéré, S. Zweegman, A. Perrot, C. Hulin +22 more
2022Haematologica24 citations Open access
Semantic Scholar
Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Patients, the IFM KRd final results.
M. Roussel, V. Lauwers-Cancès, S. Wuillème, K. Belhadj +15 more
2021Blood23 citations
Semantic Scholar
Long-term course of precancerous lesions arising in patients with gastric MALT lymphoma.
A. Rentien, Michaël Lévy, C. Copie-Bergman, C. Gagnière +7 more
2017Digestive and Liver Disease22 citations
Semantic Scholar
Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma
A. Amiot, V. Jooste, C. Gagnière, Michaël Lévy +8 more
2017Leukemia and Lymphoma21 citations
Semantic Scholar
Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial
P. Moreau, C. Hulin, M. Macro, D. Caillot +37 more
201521 citations Open access
Semantic Scholar
Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods
J. Corre, A. Perrot, C. Hulin, D. Caillot +25 more
2021Leukemia20 citations Open access
Semantic Scholar
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
M. Roussel, V. Lauwers-Cancès, M. Macro, X. Leleu +55 more
2022Blood19 citations Open access
Semantic Scholar
Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma
Laura Rosinol Dachs, B. Hébraud, A. Oriol, Anne-Laurène Colin +17 more
2018Blood19 citations Open access
Semantic Scholar
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma
A. Schavgoulidze, V. Lauwers-Cancès, A. Perrot, T. Cazaubiel +26 more
2022Haematologica18 citations Open access
Semantic Scholar
Venetoclax induces profound and sustained responses in patients with relapsed/refractory light‐chain amyloidosis
Hélène Pasquer, K. Belhadj, J. Dupuis, S. Oghina +12 more
2021British Journal of Haematology18 citations
Semantic Scholar
Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.
F. Le Bras, V. Molinier-Frenkel, A. Guellich, J. Dupuis +9 more
2017European Journal of Cancer17 citations
Semantic Scholar
Optimization of whole-body 2-[18F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma
Robert Burns, S. Mulé, P. Blanc-Durand, Mojdeh Tofighi +7 more
2021European Radiology15 citations
Semantic Scholar
Colonic mucosa-associated lymphoid tissue lymphoma: a case series
J. Tannoury, A. Amiot, F. Lemonnier, J. Dupuis +7 more
2019Leukemia and Lymphoma15 citations
Semantic Scholar
Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma
Clémentine Boccon-Gibod, A. Talbot, F. Le Bras, L. Frenzel +6 more
2020British Journal of Haematology13 citations Open access
Semantic Scholar
Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France.
T. Damy, A. Zaroui, Marie de Tournemire, M. Kharoubi +34 more
2023Archives of Cardiovascular Diseases12 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Facon×26
Invite
T. Facon — researcher profile on SciRah
P. Moreau×26
Invite
P. Moreau — researcher profile on SciRah
C. Hulin×25
Invite
C. Hulin — researcher profile on SciRah
X. Leleu×24
Invite
X. Leleu — researcher profile on SciRah

×23

Invite

M. Macro — researcher profile on SciRah

Invite

D. Caillot — researcher profile on SciRah

H. Avet-Loiseau×22

Invite

H. Avet-Loiseau — researcher profile on SciRah

Invite

M. Attal — researcher profile on SciRah

Invite

M. Roussel — researcher profile on SciRah

Lionel Karlin×19

Invite

Lionel Karlin — researcher profile on SciRah

L. Garderet×18

Invite

L. Garderet — researcher profile on SciRah

Invite

A. Stoppa — researcher profile on SciRah